Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma
CS Mitsiades, FE Davies, JP Laubach… - Journal of clinical …, 2011 - ascopubs.org
Despite tangible progress in recent years, substantial therapeutic challenges remain in
multiple myeloma (MM), particularly for patients at high risk for early relapse or death and for …
multiple myeloma (MM), particularly for patients at high risk for early relapse or death and for …
[PDF][PDF] Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma
CS Mitsiades, FE Davies, JP Laubach, D Joshua… - J Clin Oncol, 2011 - academia.edu
Despite tangible progress in recent years, substantial therapeutic challenges remain in
multiple myeloma (MM), particularly for patients at high risk for early relapse or death and for …
multiple myeloma (MM), particularly for patients at high risk for early relapse or death and for …
[PDF][PDF] Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma
CS Mitsiades, FE Davies, JP Laubach, D Joshua… - J Clin …, 2011 - scholar.archive.org
Despite tangible progress in recent years, substantial therapeutic challenges remain in
multiple myeloma (MM), particularly for patients at high risk for early relapse or death and for …
multiple myeloma (MM), particularly for patients at high risk for early relapse or death and for …
Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma
CS Mitsiades, JF San Miguel, PG Richardson - 2011 - digital.csic.es
Despite tangible progress in recent years, substantial therapeutic challenges remain in
multiple myeloma (MM), particularly for patients at high risk for early relapse or death and for …
multiple myeloma (MM), particularly for patients at high risk for early relapse or death and for …
Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma.
CS Mitsiades, FE Davies, JP Laubach… - Journal of Clinical …, 2011 - europepmc.org
Despite tangible progress in recent years, substantial therapeutic challenges remain in
multiple myeloma (MM), particularly for patients at high risk for early relapse or death and for …
multiple myeloma (MM), particularly for patients at high risk for early relapse or death and for …
[引用][C] Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma
CS MITSIADES, FE DAVIES… - Journal of clinical …, 2011 - pascal-francis.inist.fr
Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the
Development of Personalized Medicine in Myeloma CNRS Inist Pascal-Francis CNRS …
Development of Personalized Medicine in Myeloma CNRS Inist Pascal-Francis CNRS …
Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma
CS Mitsiades, FE Davies… - Journal of clinical …, 2011 - pubmed.ncbi.nlm.nih.gov
Despite tangible progress in recent years, substantial therapeutic challenges remain in
multiple myeloma (MM), particularly for patients at high risk for early relapse or death and for …
multiple myeloma (MM), particularly for patients at high risk for early relapse or death and for …
Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma
CS Mitsiades, FE Davies, JP Laubach… - Journal of Clinical …, 2011 - cir.nii.ac.jp
< jats: p> Despite tangible progress in recent years, substantial therapeutic challenges
remain in multiple myeloma (MM), particularly for patients at high risk for early relapse or …
remain in multiple myeloma (MM), particularly for patients at high risk for early relapse or …
[引用][C] Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma
M CS - J Clin Oncol, 2011 - cir.nii.ac.jp
Future directions of next-generation novel therapies, combination approaches, and the
development of personalized medicine in myeloma | CiNii Research CiNii 国立情報学研究所 …
development of personalized medicine in myeloma | CiNii Research CiNii 国立情報学研究所 …